Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES II	N BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Thomsen Jillian B. (Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH					Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR] 3. Date of Earliest Transaction (Month/Day/Year) 03/09/2016									all applic Directo	able)	g Pers	on(s) to Iss 10% Ov Other (s	vner	
													Λ	below) SVP &		ccour	below)	cer	
(Street) SAN FRANCI			94158 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							. Indivine)	·					
		Tab	ole I - No	n-Deri	vativ	e Se	curi	ties Ac	auired.	Dis	sposed o	of. or Be	neficia	allv	Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			action	tion 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)			i (A) or	or 5. Amo and 5) Securi Benefi Owned		nt of es ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(1130.4)	
Common Stock ⁽¹⁾ 03/09/2			9/2016	2016				М	15,000	A	\$6.6	65	20,	158	D				
Common Stock ⁽¹⁾ 03/09/2			9/2016	2016		S		15,000	D	\$11.7	'9 ⁽²⁾	5,158			D				
		-	Table II -								osed of, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transactio Code (Inst 8)		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		D	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow For Dire or I (I) (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amoun or Numbe of Shares	r					
Stock	\$6.65	03/09/2016			M			15,000	03/20/20	12	03/19/2016	Common	15,00	0	\$0.00	0		D	

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in early 2016 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16,
- 2. This transaction was executed in multiple trades at prices ranging from \$11.60 to \$12.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Gil M. Labrucherie, Attorneyin-Fact

03/11/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.